European Union examines new German vaccine based on nanotechnology

European Union reviews new German vaccine using nanotechnology


The European Medicines Agency (EMA) announced on Thursday that it is examining a new COVID vaccine developed by the German laboratory SK Chemicals which relies on nanotechnology to attack the virus, in anticipation of a a possible resurgence of the pandemic in the fall. 

If approved, the vaccine, called Skycovion, will be the seventh approved in the European Union, while other new vaccines are also being reviewed by the Amsterdam-based European Agency for licensing in the EU.

SK Chemicals “has submitted data on the ability of this new vaccine to trigger the production of antibodies against the initial strain of SARS-CoV-2, the virus responsible for COVID-19”, explained the EMA.

The vaccine is based on nanoparticles containing elements of the Spike protein which is the key to allowing SARS-CoV-2 to enter human cells.

The vaccine developed by SK Che micals also contains an “adjuvant” to boost the body's immune response to the vaccine, the agency said.

To date, the European Union has authorized the use of the vaccines developed by AstraZeneca, Janssen, BioNTech-Pfizer, Moderna, Novavax and Valneva which has suspended production of COVID vaccines.